Sample size estimation
vascular stiffness, T2D, CKD, T2D [
TYPE 2 DIABETES, MINERALOCORTICOIDS
During study planning and preparation, there was no sufficient clinical evidence on the effects of finerenone on vascular stiffness and other cardiovascular and renal surrogate markers in patients with T2D and CKD. Recently, a study with other MRA (Mineralocorticoid Receptor Antagonists in Type 2 Diabetes: MIRAD) showed that treatment with eplerenone for 26 weeks, compared with placebo, significantly improved cardiac structural parameters as assessed by cardiac magnetic resonance and reduced some relevant biomarker levels in patients with T2D [